Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Treasury Shares: 2019-2024

Historic Treasury Shares for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $2.6 million.

  • Beam Therapeutics' Treasury Shares fell 13.43% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 13.43%. This contributed to the annual value of $2.6 million for FY2024, which is 11.97% down from last year.
  • Per Beam Therapeutics' latest filing, its Treasury Shares stood at $2.6 million for FY2024, which was down 11.97% from $2.9 million recorded in FY2023.
  • Beam Therapeutics' Treasury Shares' 5-year high stood at $2.9 million during FY2023, with a 5-year trough of $1.1 million in FY2021.
  • For the 3-year period, Beam Therapeutics' Treasury Shares averaged around $2.4 million, with its median value being $2.6 million (2024).
  • In the last 5 years, Beam Therapeutics' Treasury Shares crashed by 51.98% in 2020 and then surged by 72.92% in 2023.
  • Over the past 5 years, Beam Therapeutics' Treasury Shares (Yearly) stood at $1.3 million in 2020, then declined by 11.69% to $1.1 million in 2021, then soared by 50.31% to $1.7 million in 2022, then spiked by 72.92% to $2.9 million in 2023, then decreased by 11.97% to $2.6 million in 2024.